# Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies

> **NCT02347228** · PHASE1 · UNKNOWN · sponsor: **Oneness Biotech Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** OB318 capsule

## Key facts

- **NCT ID:** NCT02347228
- **Lead sponsor:** Oneness Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-11
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02347228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02347228, "Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02347228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*